Abstract
P 046
Long-term complications after 106Ru-Brachytherapy for uveal melanoma
Nona Lakotka1, Lena Alekian2, Gregor Willerding1, Lothar Krause3, Joachim Wachtlin4, Nikolaos E. Bechrakis5, Michael H. Foerster1
1Augenklinik, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin, 2Praxis für Mund-, Kiefer-, Gesichtschirurgie und Oralchirurgie, Berlin, 3Augenklinik, Klinikum Dessau, Dessau, 4Augenklinik, Sankt Gertrauden-Krankenhaus, Berlin, 5Augenklinik, Medizinische Universität Innsbruck, Innsbruck, Österreich
Objective
106Ru-Brachytherapy is an established treatment modality for uveal melanoma. The aim of this study was to evaluate in a large cohort with long follow-up the local tumour control rate, secondary enucleation rate and complication rate after 106Ru-Brachytherapy for uveal melanoma.
Methods
We performed a retrospective study in 948 patients (mean age: 61.3 years) with choroidal or ciliary body melanomas primarily treated with 106Ruthenium episcleral plaques from October 1992 through December 2005. The Kaplan-Meier method was used for statistical analysis.
Results
Mean tumor size was 5.1 mm ± 2.1 mm (min: 1.0 mm; max: 12.3 mm) at the time of treatment. 17.7% of eyes showed evidence of ciliary body infiltration and 3.9% had infiltration of the iris. 3.5% of eyes had extraocular growth. The mean follow-up was 4.1 years (0.1-14.1 years). At 5 year after the treatment 55% of patients showed radiation retinopathy, neuropathy was noticed in 44%, rubeosis in 13% and secondary glaucoma in 13%. Local tumour control rates were 91% and 90% at 5 and 10 years, respectively. The eye-preservation was 95.0% and 93.7% at 5 and 10 years, respectively. The reason for secondary enucleation was tumour re-currence in 67% and radiation-related complications in 33%.
Conclusions
106Ru-Brachytherapy in the treatment of uveal melanoma with current inclusion criteria is an effective method with favourable local tumour control and eye preservation rate and an acceptable rate of complications.
Seitenanfang